The Latest

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Two biotechs — radiopharmaceuticals specialist Full-Life Technologies and immune drugmaker Accro Bioscience — raised $160 million combined in a pair of equity financings announced Monday.

    Updated 13 hours ago
  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin drug acquired in buyout misses goal in rare disease study

    Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects. 

  • Endometrial cancer cells in the uterus or cervix womb neck - closeup view 3d illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Merck ADC, licensed from China, hits mark in first big global trial

    The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.

  • An image of sodium ion channels
    Image attribution tooltip
    Permission granted by Stephanie Shiers, The University of Texas at Dallas
    Image attribution tooltip
    Deep Dive // Pain drugs

    A year after Vertex’s big launch, pain drug research faces a pivotal moment

    Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

  • India flag building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    India’s pharma industry is going global. But can it catch up to China?

    A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA hold puts Aardvark Prader-Willi drug in limbo

    The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

    Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted immune drug.

  • Orange packages of mifepristone tablets rest against each other on a table.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    Supreme Court preserves access to abortion pill by mail

    The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by mail without requiring in-person visits.

  • An illustration of necrotic muscle fiber in Duchenne muscular dystrophy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    With new data, Regenxbio to seek FDA approval of Duchenne gene therapy

    Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”

  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Biogen pushing tau drug forward despite Alzheimer’s study failure

    One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Create Medicines raises $122M to bolster in vivo CAR-T therapies

    The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

  • man in a dark blue suit speaks in the oval office
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    FDA’s leadership void leaves biotech with renewed ‘uncertainty’

    Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.

    FDA
  • A person in a dark business suit sits at a desk with a microphone.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Trump administration

    FDA chief Marty Makary resigns from agency, ending tumultuous tenure

    Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.  

    FDA
  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    SERB Pharmaceuticals is paying Hansa Biopharma 115 million euros for partial rights to a marketed medicine that helps prepare people for kidney transplants.

    Updated 14 hours ago
  • A sign spelling Bristol Myers Squibb hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

    The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts. 

  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss

    A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

    Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.

  • A micrograph of estrogen receptor staining in a breast cancer tumor sample.
    Image attribution tooltip
    Douglas Olivares via Getty Images
    Image attribution tooltip

    Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

    A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

  • layoffs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biotech layoffs are easing, but is the worst over?

    BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    GSK cuts deal with Sino to broaden reach of hepatitis B drug

    The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access to a therapy called bepirovirsen that’s important to its future.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

    Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Odyssey, on second try, snags $279M in an IPO

    After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concurrent private deal.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended

    Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.

  • A sign with Eli Lilly's logo sits outside of the company's headquarters on March 17, 2024 in Indianapolis.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly to invest extra $4.5B across Indiana manufacturing

    The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.

  • Gilead sign
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Lilly, Gilead lead pharma’s M&A boom

    Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.